Fig. 4: OMO-1 treatment increases vascular pericytes in primary tumors of a 4T1-based intraductal model. | npj Breast Cancer

Fig. 4: OMO-1 treatment increases vascular pericytes in primary tumors of a 4T1-based intraductal model.

From: OMO-1 reduces progression and enhances cisplatin efficacy in a 4T1-based non-c-MET addicted intraductal mouse model for triple-negative breast cancer

Fig. 4

Immunohistochemistry for the endothelial cell marker CD31 and the pericyte marker α-SMA and double staining immunohistochemistry for CD31 and α-SMA on paraffin sections of primary tumors from the different treatment groups at 39 days p.i. (n = 8; 2 slides per treatment group for each marker with 4 images per slide). CD31+ vessels were manually counted on 20× magnified microscopic images. The proportion of α-SMA-covered CD31+ vessels among total counted CD31+ vessels was also determined on 20× magnified microscopic images. Scale bars = 50 µm. Data are presented as the means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001.

Back to article page